Fluzoparib Added to Neoadjuvant Chemotherapy Does Not Improve Early Breast Cancer Outcomes
A single-arm phase II trial found that adding fluzoparib to neoadjuvant chemotherapy did not improve residual cancer burden grade 0/I ...
A single-arm phase II trial found that adding fluzoparib to neoadjuvant chemotherapy did not improve residual cancer burden grade 0/I ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.